AR080596A1 - Compuestos alquilamido y composiciones farmaceuticas - Google Patents

Compuestos alquilamido y composiciones farmaceuticas

Info

Publication number
AR080596A1
AR080596A1 ARP100100447A ARP100100447A AR080596A1 AR 080596 A1 AR080596 A1 AR 080596A1 AR P100100447 A ARP100100447 A AR P100100447A AR P100100447 A ARP100100447 A AR P100100447A AR 080596 A1 AR080596 A1 AR 080596A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
group
rental
compounds
Prior art date
Application number
ARP100100447A
Other languages
English (en)
Inventor
Sergio Baroni
Francesca Viti
Salvatore Bellinvia
Original Assignee
Giuliani International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani International Inc filed Critical Giuliani International Inc
Publication of AR080596A1 publication Critical patent/AR080596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) en donde X es alquileno C1-3, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados de halogeno o hidroxilo; R1 se selecciona del grupo que consiste en alquilo C1-6, cicloalquilo C3-5, alquenilo C3-6, y alquinilo C2-6; R2 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; R3 se selecciona de modo independiente, para cada aparicion del grupo que consiste en hidrogeno, alcoxi C1-6, alquilo C1-6, ciano, cicloalquilo C3-6, halogeno, hidroxilo, y nitro; R4 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; R5 es hidrogeno, alquilo C1-6; o sus sales o N-oxidos farmacéuticamente aceptables. Reivindicacion 11: Una composicion farmacéutica que comprende un compuesto, o una de sus sales o N-oxidos farmacéuticamente aceptables, de acuerdo con cualquiera de las reivindicaciones 1-10 y un portador farmacéuticamente aceptable.
ARP100100447A 2009-02-16 2010-02-16 Compuestos alquilamido y composiciones farmaceuticas AR080596A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US28746109P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
AR080596A1 true AR080596A1 (es) 2012-04-25

Family

ID=42562114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100447A AR080596A1 (es) 2009-02-16 2010-02-16 Compuestos alquilamido y composiciones farmaceuticas

Country Status (25)

Country Link
US (11) US8796334B2 (es)
EP (4) EP2396082B1 (es)
JP (4) JP5715070B2 (es)
KR (2) KR101776337B1 (es)
CN (3) CN102316932B (es)
AR (1) AR080596A1 (es)
AU (2) AU2010213095B2 (es)
BR (2) BRPI1008752B1 (es)
CA (2) CA2752623C (es)
CY (2) CY1119225T1 (es)
DK (2) DK2396081T3 (es)
EA (2) EA020856B1 (es)
ES (3) ES2806691T3 (es)
HR (2) HRP20170936T1 (es)
HU (2) HUE032999T2 (es)
IL (2) IL214664A (es)
LT (2) LT2396081T (es)
MX (3) MX2011008601A (es)
NZ (2) NZ595076A (es)
PL (1) PL2396081T3 (es)
PT (3) PT2805746T (es)
SI (2) SI2805746T1 (es)
UA (2) UA109525C2 (es)
WO (2) WO2010091894A2 (es)
ZA (1) ZA201106256B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4805556A (en) 1988-01-15 1989-02-21 Union Carbide Corporation Reactor system and method for forming uniformly large-diameter polycrystalline rods by the pyrolysis of silane
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2805746T (pt) 2009-02-16 2020-08-17 Nogra Pharma Ltd Compostos de alquilamido e utilizações dos mesmos
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
CN116602950A (zh) 2012-02-09 2023-08-18 诺格拉制药有限公司 治疗纤维化的方法
KR20150002819A (ko) 2012-04-18 2015-01-07 노그라 파마 리미티드 락토스 불내증의 치료 방법
HRP20181000T1 (hr) * 2012-09-13 2018-09-21 Nogra Pharma Limited Postupci liječenja stanja povezanih s kosom
MX2015003279A (es) * 2012-09-13 2015-07-06 Nogra Pharma Ltd Metodos para inhibir el crecimiento de vello corporal.
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
US20180273482A1 (en) 2015-04-06 2018-09-27 The Trustees Of The University Of Pennsylvania Compositions and methods for increasing, or preventing or reversing loss of, skin pigmentation in a mammalian subject
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
US20220000818A1 (en) * 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
RS66513B1 (sr) * 2019-02-08 2025-03-31 Nogra Pharma Ltd Postupak pripreme 3-(4'-aminofenil)-2-metoksipropionske kiseli-ne i njenih analoga i intermedijera
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689B1 (de) 1980-12-22 1984-07-04 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
ATE113209T1 (de) 1988-05-05 1994-11-15 Tillotts Pharma Ag Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
ES2213139T5 (es) 1990-10-22 2011-03-18 Centre For Digestive Diseases Pty Ltd Tratamiento de trastornos intestinales no inflamatorios.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
NZ249588A (en) 1992-03-17 1996-08-27 Fujisawa Pharmaceutical Co Anthelmintic agent
CA2120367C (en) 1992-06-30 2004-05-11 Howard K. Shapiro Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
EP0759750A4 (en) 1994-05-11 1998-05-27 Howard K Shapiro PREPARATIONS FOR TREATING CHRONIC FLAMMABLE DISEASES
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
HUP9900309A3 (en) 1995-03-28 1999-11-29 Janssen Pharmaceutica Nv Use of ridogrel for producing pharmaceutical compositions for the treatment of inflammatory bowel diseases
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU9002798A (en) 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) * 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
JP3854154B2 (ja) 2000-04-19 2006-12-06 ニューロテック カンパニー リミテッド 中枢神経系の急性及び慢性的損傷に起因した神経変性を防止するための化合物、組成物及び方法
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
SI1285908T1 (sl) 2000-05-29 2008-12-31 Kyorin Seiyaku Kk Substituirani fenilpropionski kislinski derivati
ES2333337T3 (es) 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
CA2430846A1 (en) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
CA2443935A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
PL369732A1 (en) 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
AU2002357729A1 (en) 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
AU2002343094A1 (en) 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2003228744A1 (en) 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
US7589232B2 (en) 2003-07-21 2009-09-15 Laboratories Serono S.A. Alkynyl aryl carboxamides
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
EP1680397A2 (en) 2003-10-28 2006-07-19 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
US20070086967A1 (en) 2003-12-03 2007-04-19 Brian Macdonald Treatment of psoriasis with rosiglitazone
CA2553775A1 (en) 2004-01-20 2005-08-11 Richard F. Harty Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) * 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
PE20060594A1 (es) 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2805746T (pt) 2009-02-16 2020-08-17 Nogra Pharma Ltd Compostos de alquilamido e utilizações dos mesmos
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
CA2841358A1 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
HK1201027A1 (en) 2011-10-17 2015-08-21 加利福尼亚大学董事会 Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods
EP2773378B1 (en) 2011-10-31 2016-08-10 Larsen, Claus Selch Prodrugs of non-steroid anti-inflammatory agents (nsaids)
CN116602950A (zh) 2012-02-09 2023-08-18 诺格拉制药有限公司 治疗纤维化的方法
KR20150002819A (ko) 2012-04-18 2015-01-07 노그라 파마 리미티드 락토스 불내증의 치료 방법
WO2013168438A1 (ja) 2012-05-10 2013-11-14 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
CN104619687A (zh) 2012-06-01 2015-05-13 诺格拉制药有限公司 能够调节t-细胞应答的双环杂环及其使用方法
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
HRP20181000T1 (hr) 2012-09-13 2018-09-21 Nogra Pharma Limited Postupci liječenja stanja povezanih s kosom
MX2015003279A (es) 2012-09-13 2015-07-06 Nogra Pharma Ltd Metodos para inhibir el crecimiento de vello corporal.
HUE030707T2 (en) 2013-03-26 2017-05-29 Lipid Therapeutics Gmbh Pharmaceutical composition containing phosphatidylcholine for the treatment of ulcerative colon inflammation
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
CA2986611C (en) 2015-06-15 2023-10-03 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
CA3014575A1 (en) 2016-02-26 2017-08-31 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
ZA201106256B (en) 2012-05-30
JP5715070B2 (ja) 2015-05-07
IL214665A (en) 2017-02-28
UA105037C2 (uk) 2014-04-10
EP2805746A1 (en) 2014-11-26
US20200383942A1 (en) 2020-12-10
HUE032999T2 (hu) 2017-11-28
EP2396082A2 (en) 2011-12-21
EA020198B1 (ru) 2014-09-30
DK2805746T3 (da) 2020-08-10
US20120053244A1 (en) 2012-03-01
CY1123213T1 (el) 2021-12-31
EP2805746B1 (en) 2020-05-06
AU2010213095B2 (en) 2015-09-17
CN102316932B (zh) 2014-07-09
CA2752626A1 (en) 2010-08-19
DK2396081T3 (en) 2017-07-10
KR20110120946A (ko) 2011-11-04
KR101800901B1 (ko) 2017-11-23
CA2752623A1 (en) 2010-08-19
EP2396081B1 (en) 2017-04-05
US20150148418A1 (en) 2015-05-28
US20180369178A1 (en) 2018-12-27
CN102316931A (zh) 2012-01-11
BRPI1011226A2 (pt) 2016-03-15
US20200188340A1 (en) 2020-06-18
US9511041B2 (en) 2016-12-06
US10398667B2 (en) 2019-09-03
KR101776337B1 (ko) 2017-09-07
MX2011008601A (es) 2011-09-09
US20190269637A1 (en) 2019-09-05
EA201171063A1 (ru) 2012-01-30
PT2396082E (pt) 2013-10-03
BRPI1008752B1 (pt) 2020-02-11
US20120053245A1 (en) 2012-03-01
IL214665A0 (en) 2011-09-27
JP2015155427A (ja) 2015-08-27
LT2805746T (lt) 2020-09-25
EA201171062A1 (ru) 2012-01-30
AU2010213093A1 (en) 2011-09-08
CA2752626C (en) 2018-03-27
MX381002B (es) 2025-03-12
MX2011008602A (es) 2011-09-09
JP5645851B2 (ja) 2014-12-24
US20150051285A1 (en) 2015-02-19
CN104666288B (zh) 2017-08-04
EP2396082B1 (en) 2013-07-31
US20170172956A1 (en) 2017-06-22
US20220354809A1 (en) 2022-11-10
SI2805746T1 (sl) 2020-10-30
JP2012517969A (ja) 2012-08-09
ES2630044T3 (es) 2017-08-17
US10959970B2 (en) 2021-03-30
CA2752623C (en) 2017-07-04
WO2010091894A2 (en) 2010-08-19
US8796334B2 (en) 2014-08-05
BRPI1011226B1 (pt) 2019-10-29
WO2010091894A3 (en) 2010-11-11
EP2396081A2 (en) 2011-12-21
SI2396081T1 (sl) 2017-09-29
HRP20201184T1 (hr) 2020-12-11
US8754127B2 (en) 2014-06-17
UA109525C2 (xx) 2015-09-10
JP5820030B2 (ja) 2015-11-24
EA020856B1 (ru) 2015-02-27
IL214664A (en) 2015-09-24
BRPI1008752A2 (pt) 2016-03-08
HRP20170936T1 (hr) 2017-09-22
PL2396081T3 (pl) 2017-10-31
NZ595080A (en) 2013-09-27
PT2396081T (pt) 2017-07-11
ES2806691T3 (es) 2021-02-18
CY1119225T1 (el) 2018-02-14
JP2014237692A (ja) 2014-12-18
LT2396081T (lt) 2017-09-11
JP2012517968A (ja) 2012-08-09
CN102316932A (zh) 2012-01-11
HUE050267T2 (hu) 2020-11-30
ES2429143T3 (es) 2013-11-13
PT2805746T (pt) 2020-08-17
CN102316931B (zh) 2014-11-19
WO2010091892A2 (en) 2010-08-19
US20160338927A1 (en) 2016-11-24
IL214664A0 (en) 2011-09-27
US10137101B2 (en) 2018-11-27
AU2010213093B2 (en) 2016-01-07
AU2010213095A1 (en) 2011-09-08
EP3744398A1 (en) 2020-12-02
NZ595076A (en) 2013-09-27
CN104666288A (zh) 2015-06-03
WO2010091892A3 (en) 2010-10-21
KR20110120945A (ko) 2011-11-04
US9901557B2 (en) 2018-02-27

Similar Documents

Publication Publication Date Title
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR073136A1 (es) Compuestos de pirrol
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BR112014010644A2 (pt) novos derivados de aril-quinolina
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp

Legal Events

Date Code Title Description
FG Grant, registration